MetrioPharm Investor Relations News QIII 2022

MetrioPharm at BioPharm America in Boston, USA

MetrioPharm's CEO Thomas Christély and MetrioPharm's CSO Dr. Wolfgang Brysch visited BioPharm America in Boston in late September 2022. BioPharm America is a partnering conference where life science innovators partner to fuel the future of drug development. Now in its 15th year, the event was held in-person taking place September 28–29, 2022 as part of Biotech Week Boston. Subsequently the event featured two digital days. The program focused on innovation, partnering, and investing with over 30 sessions, including presentations from emerging companies.

MetrioPharm visited BioPharm America to meet potential pharma partners for planned fixed-dose combination therapies. The goal is to combine drugs of existing standard therapies at lower doses with MP1032 in a single pill to produce novel drugs with improved efficacy and fewer side effects.

Mr. Christély and Dr. Brysch also took the opportunity to introduce MetrioPharm's new corporate deck to potential partners. The new corporate deck gives an overview over the company's next strategic steps and can be found here. Potential pharma partners were also informed about the current status of the company's ongoing Phase II study in COVID-19. The last patient was examined in late July, first top line data will be published in Q4 2022.

MetrioPharm AG Company Calendar in QIV 2022

18th October 2022: Sofinnova BioPartnering, Tokyo, Japan (Digital)
24-26th October 2022: Bio-Europe, Leipzig, Germany
11-12th November 2022: China Bio Partnering Forum, Beijing, China (Digital)
14th November 2022: Inv€$tival Showcase, London, UK
15-17th November 2022: Jefferies Healthcare Conference, London, UK

MetrioPharm AG informs

MetrioPharm uses various channels to inform its shareholders:

  • In addition to the quarterly newsletter, we also keep you informed about current events in the company with press releases. The press releases can also be found on our website here. If you have not yet been added to our distribution list for press releases, please send us an e-mail at invest@metriopharm.com and we will add you to the distribution list as soon as possible.
  • In November 2021, MetrioPharm signed a grant agreement from the European Commission for € 7.9 million. The project "iMPact" was among the 6 initiatives selected by the Commission to work on compounds for the treatment of SARS-CoV-2. The project includes the conduct of a Phase II clinical trial with MetrioPharm's lead compound MP1032 against COVID-19, as well as preclinical studies on the effect of MP1032 on mutant variants of SARS-CoV-2. More information on the iMPact project can be found here.
  • You can also network with MetrioPharm via LinkedIn. We use our LinkedIn profile to inform shareholders, experts and business partners about the latest company developments. Please feel free to include us in your LinkedIn community by invitation.


Your contact:

MetrioPharm AG Eva Brysch Investor Relations Managerin          

Lia Petridou
Corporate Communications & Press Relations

T +49 (0) 30 33 84 395 53
F +49 (0) 30 33 84 395 99
E press@metriopharm.com
W www.metriopharm.com



MetrioPharm AG Download PDF